Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron Pharmaceuticals has started two Phase III trials evaluating the safety and efficacy of aflibercept in combination with standard chemotherapy regimens in patients with prostate cancer and non-small cell lung cancer.
Subscribe to our email newsletter
Aflibercept is an anti-angiogenic agent targeting vascular endothelial growth factor (VEGF), currently being developed by New York-based Regeneron in collaboration with Sanofi-Aventis. These two trials will be double-blind and placebo-controlled.
Sanofi-aventis will provide an update of the broad-based clinical development program planned for aflibercept, and additional details on these two trials, at its R&D day meeting scheduled to be held in Paris, France on September 17, 2007.